Free Trial
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Aurinia Pharmaceuticals logo
$8.04 +0.45 (+5.86%)
As of 12:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Key Stats

Today's Range
$7.62
$8.01
50-Day Range
$7.47
$8.64
52-Week Range
$5.20
$10.67
Volume
719,437 shs
Average Volume
1.38 million shs
Market Capitalization
$1.09 billion
P/E Ratio
28.70
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Buy

Company Overview

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

AUPH MarketRank™: 

Aurinia Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 423rd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aurinia Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Aurinia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aurinia Pharmaceuticals is 27.61, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.99.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aurinia Pharmaceuticals is 27.61, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.97.

  • Price to Book Value per Share Ratio

    Aurinia Pharmaceuticals has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Aurinia Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    8.82% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently increased by 0.29%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Aurinia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Aurinia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.82% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently increased by 0.29%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Aurinia Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 29 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

  • Read more about Aurinia Pharmaceuticals' insider trading history.
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Stock News Headlines

Aurinia Pharmaceuticals (AUPH) Gets a Buy from TD Cowen
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

AUPH Stock Analysis - Frequently Asked Questions

Aurinia Pharmaceuticals' stock was trading at $8.98 at the beginning of the year. Since then, AUPH stock has decreased by 13.6% and is now trading at $7.7630.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its quarterly earnings data on Monday, May, 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The biotechnology company had revenue of $62.47 million for the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a trailing twelve-month return on equity of 14.27% and a net margin of 16.11%.
Read the conference call transcript
.

Aurinia Pharmaceuticals' top institutional shareholders include City Center Advisors LLC (0.02%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan.
View institutional ownership trends
.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
5/12/2025
Today
7/09/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AUPH
CIK
1600620
Employees
300
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$10.00
Potential Upside/Downside
+45.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
28.11
Forward P/E Ratio
71.77
P/E Growth
N/A
Net Income
$5.75 million
Pretax Margin
16.91%

Debt

Sales & Book Value

Annual Sales
$247.30 million
Cash Flow
$0.33 per share
Price / Cash Flow
24.22
Book Value
$2.68 per share
Price / Book
2.95

Miscellaneous

Free Float
118,621,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
1.16

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:AUPH) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners